Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ALSERES PHARMACEUTICALS INC (ALSE)
|
Add to portfolio |
|
|
|
| Price: |
$0.01
| | Metrics |
| OS: |
30.6
|
M
| |
|
|
| Market cap: |
$306.4
|
k
| |
|
|
|
Net cash:
|
$68.1
|
k
| |
$0.00
|
per share
|
|
EV:
|
$238.3
|
k
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($3.7)
|
M
| |
|
|
|
EBIT
|
($843.8)
|
k
| |
|
|
| EPS |
($0.03)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| Revenues | 0.5 | 0.5 | 2.3 | 0.0 | 3.7 | 10.9 | 10.5 | 18.5 |
| Revenue growth | -10.7% | -77.4% | | -100.0% | -65.9% | 3.6% | -43.5% | 202.5% |
| Cost of goods sold | -1.4 | -1.8 | 0.0 | 0.0 | 4.6 | 10.9 | 10.5 | 18.5 |
| Gross profit | 1.9 | 2.3 | 2.3 | 0.0 | -0.9 | 0.0 | 0.0 | 0.0 |
| Gross margin | 405.2% | 436.9% | 100.0% | | -24.9% | 0.0% | 0.0% | 0.0% |
| Research and development | | 0.1 | 0.1 | 0.5 | | | | |
| General and administrative | 1.4 | 1.7 | 2.0 | 2.7 | 4.6 | 7.9 | 8.4 | 7.9 |
| EBIT | -0.6 | -1.2 | -1.6 | -3.1 | -8.3 | -18.7 | -18.9 | -26.4 |
| EBIT margin | -119.2% | -228.4% | -66.7% | | -224.9% | -172.4% | -180.2% | -142.6% |
| Pre-tax income | -0.9 | -1.6 | -2.9 | 0.5 | -10.8 | -20.8 | -19.5 | -26.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -0.9 | -1.6 | -2.9 | 0.1 | -10.8 | -20.8 | -19.5 | -26.4 |
| Net margin | -198.7% | -310.0% | -122.8% | | -291.0% | -192.1% | -186.6% | -142.2% |
| |
| Diluted EPS | ($0.03) | ($0.05) | ($0.10) | $0.00 | ($0.46) | ($1.00) | ($1.04) | ($1.59) |
| Shares outstanding (diluted) | 30.6 | 30.6 | 29.6 | 31.6 | 23.4 | 20.9 | 18.9 | 16.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|